New analyses back Amvuttra as first-line treatment for complex heart cases

Injectable therapy shows consistent benefits across high-risk ATTR-CM groups

New analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial treatment for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) who have risk factors such as abnormal heart rhythms or low blood pressure.

The injectable therapy was found to lower the risk of death or recurrent cardiovascular events — acute, sudden incidents causing injury to the heart or brain, primarily due to interrupted blood flow — among ATTR-CM patients with these issues.